NCT07553442RecruitingPhase 2
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 93 (estimated)
- First submitted
- 22 Apr 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2028
- Lead sponsor
- Alnylam Pharmaceuticals
- Diseases
- High blood pressure
- NCT number
- NCT07553442
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 93
- From Apr 2026 to the primary completion date, Apr 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Part A: Inclusion Criteria
- Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg
- Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications
- Part B: Inclusion Criteria
- Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
- Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks
- Both Parts: Exclusion Criteria
- Has known secondary hypertension or serum potassium more than 5 mmol/L
- Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2
- Note: other protocol defined inclusion / exclusion criteria apply
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Lake Forest | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Savannah | United States | Active, not recruiting |
| - Coordinator of this site? Confirm its status | Tampa | United States | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.